Dr Susan Currie


Strathclyde Institute of Pharmacy and Biomedical Sciences

Personal statement

Susan Currie obtained her PhD in Biochemistry (cellular signalling and molecular pharmacology) from the University of Glasgow in 1992 then spent two years at Lilly Research Laboratories, USA, where she studied the role of phospholipase A² in mast cell activation. She returned to the University of Glasgow in 1994 to join the then newly formed Clinical Research Initiative in heart disease and became a founder member of the school of cardiovascular studies in Glasgow. During this time she progressed from postdoctoral researcher to Principal Investigator examining the role of Calcium/calmodulin protein kinase ll (CaMKll) in cardiac hypertrophy and heart failure. She moved to the University of Strathclyde in 2005 as a Lecturer in Physiology & Pharmacology and established an independent cardiovascular signalling research group with principal interests in CaMKll modulation of cardiac calcium handling and cardiac inflammation. Dr Currie is currently a Reader/Associate Professor within Strathclyde Institute of Pharmacy & Biomedical Sciences and CaMKll as a therapeutic target in cardiac disease remains a key focus of research. More recent research interests include cardiotoxicity in the context of safety pharmacology and devices as well as altered cardiovascular function in ageing.

Dr Currie is currently research group leader for the Cellular Basis of Disease research group within Strathclyde Institute of Pharmacy & Biomedical Sciences. Externally she is chair of the Scottish Cardiovascular Forum (since 2011), is on the committee for the British Society of Cardiovascular Research and is a Fellow of the Physiological Society. Fellowship was awarded in 2017 in recognition of her contribution to cardiovascular research and the discipline of Physiology. She sits on the editorial boards for a range of scientific journals and regularly reviews research funding applications for a number of research councils and charities. She currently teaches on a wide range of classes across both the MPharm and Biomedical Sciences programmes at the University of Strathclyde and coordinates classes on the MPharm programme. She was awarded Fellowship of the Higher Education Academy in 2008.

Dr Currie previously directed the collaborative MPharm programme between the University of Strathclyde and the International Medical University (IMU) in Kuala Lumpur (2012-2017), acting as MPharm representative on the internationalisation committee and was Deputy Director of the MPharm programme at the University of Strathclyde (2012-2018). She is currently Director of Equality, Diversity and Inclusion within Strathclyde Institute of Pharmacy & Biomedical Sciences.


Anti-Cancer Drug-Induced Cardiotoxicity
Currie Susan, Cunningham Margaret Rose, Cross Michael, Maddock Helen Louise
Concentration- and time-dependent effects of cobalt in rat and human ventricular cardiac fibroblasts
MacMillan S, Olatunji Z O, Bosakhar Z Y, MacKenzie G, Grant M H, Tate R, Macquaide N, Currie S
Acta Physiologica Vol 236, pp. 614 (2022)
Cobalt-mediated contractile dysfunction in adult hearts and consequent effects on cardiomyocyte calcium transients
MacMillan S, Olatunji Z O, Bosakhar Z Y, MacKenzie G, Grant M H, Tate R, Macquaide N, Currie S
Acta Physiologica Vol 236, pp. 922 (2022)
Global longitudinal strain is compromised in patients with elevated blood cobalt levels secondary to metal-on-metal hip implants
Jenkinson M RJ, Meek RMD, MacMillan S, Tate R, Grant MH, Currie S
Europhysiology 2022 (2022)
Editorial: Arteriogenesis and collateral remodelling in ischaemic disease
Wu Junxi, Zhu Dongxing, Currie Susan
Frontiers in Cardiovascular Medicine Vol 9 (2022)
Characterising endothelial CaMKII oxidation in a cellular model of inflammation to investigate the therapeutic potential of a novel anti-oxidant stent coating
Longhorn Daniel, McCormick Christopher, Currie Susan
36th Annual Meeting of the International Society for Heart Research European Section International Society of Heart Research (2021)

More publications

Professional activities

Allyship in Higher Education and Research
Heart Research UK Scotland annual event
Novel off-target effects of doxorubicin on cardiovascular gap-junctional proteins
Scottish Cardiovascular Forum 2021
Scottish Cardiovascular Forum 2021
Scottish Cardiovascular Forum 2021

More professional activities


Heart Damage Caused by Cancer and Anti-cancer Drugs (Vacation Scholarship)
Cunningham, Margaret Rose (Principal Investigator) Bauer, Ralf (Co-investigator) Currie, Susan (Co-investigator)
27-Jan-2022 - 19-Jan-2022
Remodelling of E-C coupling in heart failure with preserved ejection fraction (HFpEF)
Currie, Susan (Co-investigator)
01-Jan-2021 - 30-Jan-2024
Cross-examining interplay between High Mobility Group Box 1 (HMGB1) and coagulation: Defining a role for G protein-coupled receptors (GPCRs) in this complex Coag-Inflammatory nexus
BOSAKHAR, Zainab Y H A H A (Post Grad Student) Currie, Susan (Co-investigator) Plevin, Robin (Academic) Cunningham, Margaret Rose (Principal Investigator)
01-Jan-2020 - 30-Jan-2023
Doctoral Training Partnership 2020-2021 University of Strathclyde | Geiser, Angéline
Gould, Gwyn (Principal Investigator) Currie, Susan (Co-investigator) Geiser, Angéline (Research Co-investigator)
01-Jan-2020 - 01-Jan-2024
Investigating connexin 43 expression in adult cardiac fibroblasts
Currie, Susan (Principal Investigator)
31-Jan-2019 - 30-Jan-2019
Investigating the biomolecular complexity of drug-induced cardiotoxicity by fingerprinting single cell and cardiac spheroid mass spectral information using Time-of-flight Secondary Ion Mass Spectrometry (TOF-SIMS)
Cunningham, Margaret Rose (Principal Investigator) Veerman, Ben (Post Grad Student) Johnston, Blair (Co-investigator) Currie, Susan (Co-investigator)
The aim of this project is to significantly advance upon ongoing efforts in understanding drug-induced cardiotoxicity not only at the single cell level but in a multicellular model that may better reflect the cellular microenvironment of the heart. Extending studies to assess the metabolite changes in the multicellular environment in response to cancer therapeutics may reveal events integral to toxicity which may lead to new knowledge to develop ways to minimise or prevent cellular toxicity in the cardiac niche.
01-Jan-2019 - 28-Jan-2022

More projects


Strathclyde Institute of Pharmacy and Biomedical Sciences
Hamnett Wing

Location Map

View University of Strathclyde in a larger map